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Sarah K. Flaherty, BS, Murray L. Shames, MD, Brad L. Johnson, MD, and Martin R. Back, MD,
Tampa, Fla
Purpose: This study was conducted to evaluate the impact of duplex ultrasound surveillance on the patency of
femorofemoral bypasses performed for symptomatic peripheral arterial occlusive disease (PAOD).
Methods:A retrospective review was conducted of 108 patients (78men, 30 women) with a mean age of 62 10 years who
underwent femorofemoral prosthetic (n  100) or vein (n  8) bypass grafting for symptomatic PAOD (claudication,
38%; rest pain, 41%; tissue loss, 11%; infection, 10%) during a 10-year period. Prior or concomitant inflow iliac artery
stenting was performed in 26 patients (24%), and a redo femorofemoral bypass was performed in 19 patients (18%).
Duplex ultrasound surveillance of the reconstruction was performed at 6-month intervals to assess patency, graft
(midgraft peak systolic flow velocity) hemodynamics, and identify inflow or outflow stenotic lesions. Repair was
recommended for a stenosis with a peak systolic velocity (PSV)>300 cm/s and a PSV ratio>3.5. Life-table analysis was
used to estimate primary, assisted-primary, and secondary graft patency.
Results: During a mean 40-month follow-up (range, 2 to 120 months), 31 bypasses (29%) were revised: 19 duplex-
detected stenosis involving the inflow iliac artery (n  15) or anastomotic stenosis (n  4), or both, 11 for graft
thrombosis, and 1 for graft infection. Abnormal inflow iliac (PSV >300 cm/s) hemodynamics or a mid-graft PSV <60
cm/s was measured in eight of 11 grafts before thrombosis. Mean time to revision was 30  17 months. The primary
graft patency at 1, 3, and 5 years was 86%, 78%, and 62%, respectively. Correction of duplex-detected stenosis resulted in
assisted-primary patency of 95% at 1 year and 88% at 3 and 5 years (P < .0001, log-rank). Secondary graft patency was
98% at 1 year and 93% at 3 and 5 years.
Conclusions: Vascular laboratory surveillance after femorofemoral bypass that included duplex ultrasound imaging of
the inflow iliac artery and graft accurately identified failing grafts. A duplex-detected identified stenosis with a PSV>300
cm/s correlated with failure, and repair of identified lesions was associated with excellent 5-year patency. (J Vasc Surg
2006;44:496-502.)Our vascular group has previously reported the benefits
of duplex ultrasound surveillance after infrainguinal vein
bypass for symptomatic peripheral arterial occlusive disease
(PAOD), repair of popliteal aneurysm, and iliac artery
angioplasty.1-4 In contrast, data on the efficacy of ultra-
sound surveillance after lower extremity prosthetic bypass
grafting are inconsistent, with even advocates for routine
surveillance admitting the benefit of increased patency is
less than after vein bypass grafting. Our policy is to advise
repair-site surveillance of all peripheral interventions, both
endovascular and open repairs and bypasses, based on a
rationale that intervention failure occurs in one quarter to
one third of patients, and secondary procedures to repair
duplex-detected abnormalities are safe, effective, and asso-
ciated with uninterrupted patency.
The patency rate of femorofemoral prosthetic bypass
grafting is inferior to aortofemoral bypass, with failure
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496attributed to higher rates of occlusive disease progression in
the inflow iliac and outflow femoral arteries.5-11 However,
recent reports of femorofemoral bypass performed using
deep femoropopliteal vein or in conjunction with aortou-
niiliac stent-graft abdominal aortic aneurysm (AAA) repair
have indicated 5-year primary graft patency 85%.5,6 The
excellent graft patency of in these clinical scenarios suggests
the increased failure rate of femorofemoral bypass for symp-
tomatic PAOD is likely a result of acquired lesions that
reduce graft flow and lead to thrombosis.
In this retrospective, observational study, we evaluated
diagnostic criteria for intervention based on duplex ultra-
sound surveillance after femorofemoral bypass for symp-
tomatic PAOD. The vascular laboratory surveillance proto-
col assessed changes in graft hemodynamics and used
duplex ultrasound imaging to identify developing stenosis
in the inflow iliac or outflow femoral arteries and in graft
anastomotic sites. This experience was used to determine
the failure modes of femorofemoral bypass and outcomes
after intervention to repair duplex-detected stenosis.
MATERIALS AND METHODS
Patient demographics. A retrospective review was
conducted of 108 patients (72% men) with a mean age of
62.4 10.1 years who underwent femorofemoral pros-
thetic (n  100) or vein (n  8) bypass grafting at the
Tampa General Hospital or the James A. Haley Veterans
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2005. Bypass grafting was performed to alleviate symptom-
atic PAOD, consisting of claudication in 38%, rest pain in
41%, tissue loss in 11%, and infection in 10%. Associated
medical conditions included hypertension in 73 (67%) pa-
tients, diabetes mellitus in 27 (25%), and hyperlipidemia in
49 (45%).
Previous procedures consisted of coronary artery by-
pass grafting (CABG) in 9 patients (8%) a recipient limb
forefoot or below-knee amputation in 15 (14%), and in-
frainguinal bypass in 27 (25%), including femorofemoral
bypass in 19 (18%) and femoral-distal bypass in 8. In nine
patients, the femorofemoral bypass was performed after
thrombosis of an aortofemoral graft limb that was could
not be reopened by thrombectomy. In an additional 27
patients (25%), stent angioplasty of the inflow iliac artery
had been done either before or in conjunction with the
femorofemoral bypass grafting procedure. Overall, 58
(54%) of the 108 patients had undergone a prior lower limb
revascularization procedure.
Duplex ultrasound surveillance protocol. Patients
were enrolled in a noninvasive vascular laboratory surveil-
lance protocol that included clinical assessment by patient
history and physical examination of limb arterial circula-
tion, measurement of Doppler-derived ankle systolic pres-
sure (ankle-brachial index), and color duplex scanning of
the arterial bypass, including the inflow and outflow arter-
ies, as appropriate.1,2,4 Testing was performed in a vascular
laboratory accredited by the Intersocietal Commission for
Accreditation of Vascular Laboratories before or, typically,
30 days of hospital discharge and then at 6-month inter-
vals.
Color duplex ultrasound imaging using 2.5-MHz to
7-MHz annular, curved, or linear array transducers was
performed to detect stenosis in the aorta or inflow and
iliofemoral arterial segment and estimate stenosis severity
based on velocity spectra changes. If the inflow iliofemoral
artery Doppler spectra were normal (ie, multiphasic or
triphasic), direct imaging of the inflow iliac artery was not
performed.
The bypass graft, and inflow and outflow anastomotic
regions were imaged at every surveillance visit, and velocity
spectra were recorded at a 60° Doppler angle from imaged
stenotic segments and at preselected sites: inflow external
iliac artery, proximal and distal anastomosis, mid-graft ve-
locity, and outflow (common femoral, superficial femoral,
deep femoral) arteries, if patent.
When color or power Doppler imaging identified a
stenosis, the peak systolic velocity (PSV) and ratio of PSV
(Vr) across the stenosis was calculated. On the basis of prior
infrainguinal bypass and iliac stent surveillance experience,
the finding of duplex-detected stenosis with a PSV 300
cm/s and Vr3.5 was interpreted as abnormal and predic-
tive of a pressure-reducing 70% stenosis, and consider-
ation for repair or further diagnostic testing (angiography)
was recommended. If duplex testing identified a less severe
but50% stenosis (PSV of 180 cm/s to 300 cm/s, Vr2),
the time interval between graft surveillance studies wasreduced to 2 to 3 months to allow detection of stenosis
progression. Midgraft PSV was also recorded with the
hypothesis that a level60 cm/s indicated low-flow hemo-
dynamics and increased risk for thrombosis.
Treatment of duplex-detected abnormalities. Patients
with duplex-detected inflow iliac artery stenosis (PSV
300 cm/s, Vr 3.5) underwent further evaluation or
treatment of identified abnormalities based on surgeon and
patient preference. In general, angiography was used to
confirm duplex-detected lesions. Ipsilateral femoral anasto-
mosis puncture was followed by fluoroscopic-controlled
guidewire advancement through the lesion. Percutaneous
interventions used self-expanding nitinol stent angioplasty
of the stenotic artery segment if the resting systolic pressure
gradient was15 mmHg or if the pressure gradient across
the stenosis was30mmHgwith arterial administration of
papaverine hydrochloride (30 mg). Balloon angioplasty
was used selectively for treatment of iliac stent stenosis.
Technical success after angioplasty was determined by res-
olution of the preintervention gradient. Acquired stenotic
lesions involving anastomotic sites or outflow arteries gen-
erally were treated by open surgical repair.
Data analysis. Hospital, vascular clinic, and vascular
laboratory patient records were retrospectively reviewed.
Adverse patient outcomes, including death, graft thrombo-
sis, graft revision, and amputation were recorded through-
out a mean follow-up interval of 40 months (range, 3 to
120 months). The level or changes in midgraft PSV to60
cm/s were correlated with duplex results, including the
identification of a graft stenosis or the occurrence of graft
thrombosis, by using the last recorded midgraft PSV before
revision procedure or thrombosis.
Femorofemoral bypass graft primary, primary-assisted,
and secondary patency rates were estimated by Kaplan-
Meier life-table analysis. Differences in patency rates were
compared by using the log rank and generalized Wilcoxon
tests,12 and 2 analysis was used to determine differences in
revision rate related to duplex findings of a PSV300 cm/s
or a midgraft PSV 60 cm/s. Student’s t test was used to
compare ankle-brachial indices (ABIs) and midgraft PSVs
in revised vs nonrevised femorofemoral bypasses. P  .05
was considered significant.
RESULTS
Outcomes at 30 days. All grafts were patent at hospi-
tal discharge according to predischarge duplex scan testing,
and no bypass revisions were performed 30 days of the
procedure. Secondary surgical site procedures, consisting
of skin and subcutaneous tissue débridement with primary
wound closure, were performed in 10 patients (9.3%) for
superficial wound infection (n 8) or to treat lymph fistula
(n  2). No amputations below or above the knee were
performed.
Results of initial duplex surveillance studies were inter-
preted as normal in all but one patient in whom an inflow
iliac artery stenosis (380 cm/s PSV) was demonstrated.
This lesion was not corrected immediately because the
ABIs were0.85, but subsequent duplex surveillance doc-
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months after the procedure.
Outcomes after 30 days. Thirty (28%) patients, all of
whom had undergone prosthetic (polytetrafluoroethylene
[PTFE]) femorofemoral bypass, had a secondary procedure
to treat stenosis or graft thrombosis. The mean time to
intervention was 30  127 months (range, 2 to 83
months). Problems that were repaired included graft
thrombosis confirmed by duplex examination (n 11), the
development of a new or progressive inflow iliac artery
stenosis (n  15), graft anastomotic stenosis (n  2), and
synchronous inflow-outflow graft stenosis (n 2) detected
by serial duplex testing.
Five of the 19 patients with iliac artery or graft anasto-
motic stenosis testified to new or worsened claudication
symptoms. All patients presenting with graft thrombosis
were symptomatic, and the ABI had decreased 0.2. In
contrast, results of duplex surveillance in the eight patients
who underwent femorofemoral bypass using deep (femo-
ropopliteal) vein were normal, and no secondary proce-
dures or thrombosis occurred.
Finally, a segmental PTFE graft infection developed in
one patient after puncture performed for coronary artery
stent angioplasty. This was successfully treated by graft
excision and in situ femoropopliteal vein graft replacement.
Surveillance duplex results. The results of prior du-
plex surveillance were abnormal (PSV300 cm/s) in eight
(73%) of the 11 patients presenting with graft thrombosis
(inflow stenosis in 7; outflow stenosis in 1) who had sur-
veillance studies 6 months of graft thrombosis (Table I).
These lesions had not been repaired for various reasons,
including surgeon assessment that the lesion was not suffi-
ciently severe to warrant immediate intervention, patient
declining further testing, or the patient did not return for
surveillance to identify stenosis progression. Three patients
presenting with graft thrombosis did not have recent (6
month) duplex ultrasound testing, but an outflow stenosis
was identified and corrected at the time of graft thrombec-
tomy/revision in two of these patients. Five of 11 graft
thrombosis occurred6months of the grafting procedure,
and all but one of these patients had had a prior surveillance
study interpreted as abnormal. Seven of nine thrombosed
grafts with prior measured midgraft PSVs had values 60
cm/s recorded (range, 25 to 56 cm/s).
Duplex surveillance identified 30 reconstructions with
Table I. Incidence of abnormal velocity spectra*
recorded from eight femorofemoral bypasses before
thrombosis (6 months after the primary procedure)
Timing
post-op No
Iliac PSV
300 cm/s
Graft PSV
300 cm/s
Midgraft PSV
60 cm/s
6 months 5 4 — 4
6 months 3 2 1 1
*Defined as peak systolic velocity (PSV) 300 cm/s, mid-graft PSV 60
cm/s.a PSV 300 cm/s stenosis (Table II). In 24 patients, a graftrevision was performed for either stenosis (n  17) or
thrombosis (n 7). Stenosis was detected in eight (30%) of
27 iliac stents and in 16 (20%) of 81 native iliac arteries. As
previously noted, 17 iliac stenoses identified by surveillance
were corrected, all using endovascular interventions, be-
cause of a measured resting pressure gradient15mmHg.
The four anastomotic stenoses identified during surveil-
lance were repaired in two patients each by open graft
revision or balloon angioplasty. In six patients, the stenosis
identified on duplex imaging has yet to be corrected be-
cause PSVs or Vr values were at, or slightly above, the
threshold levels. The diagnostic accuracy of duplex surveil-
lance for predicting graft stenosis requiring repair or graft
thrombosis was 80% (positive predictive value).
The mean time to revision was 18  14 months for
graft thrombosis and 36  30 months for surveillance-
identified stenosis. After intervention, duplex surveillance
studies demonstrated normal or improved (PSV 300
cm/s) velocity spectra in all patients. Secondary procedures
for surveillance-detected stenosis or graft thrombosis were
notmore common in patients with prior iliac stenting (P
.98), an occluded outflow superficial femoral artery, or an
ABI 0.7 (P  .34) in the recipient limb of the femoro-
femoral bypass.
Midgraft PSVwas60 cm/s in 5 (62%) of 8 grafts with
prior surveillance studies revised for thrombosis, 7 (32%) of
19 grafts revised for iliac artery or graft anastomotic steno-
sis, 1 (17%) of 6 grafts with nonrevised iliac stenosis, and 10
(14%) of 72 grafts with normal results on duplex scans. A
midgraft velocity60 cm/s correlated (P .03) with graft
revision for stenosis or thrombosis (Table II, Fig 1). Mean
midgraft PSV values were similar (P  .1) in nonrevised
(76  28 cm/s) and revised grafts before the revision
procedure (62  37 cm/s), but when a threshold value of
60 cm/s was analyzed, 14 of 26 bypasses with a midgraft
PSV 60 cm/s required revision or thrombosed.
Survival and graft patency. Fifteen patients (14%)
died during the follow-up period at a mean time of 27 
26 months. Primary graft patency rates at 1, 3, and 5 years
Table II. Incidence of abnormal velocity spectra*
recorded from the inflow iliac artery of 118
femorofemoral bypasses
Treatment
group
Iliac/Graft PSV
(cm/s)
Midgraft PSV
(cm/s)
No 300 300 NP 60 60 ND
No revision 78 52 6 20 13 49 16
Revised† 30 5 24 1 14 12 4
P (2) .001 .03
NP, Not performed because of a normal femoral artery Doppler spectra;
ND, data not recorded on vascular laboratory study sheet.
*Defined as peak systolic velocity (PSV) 300 cm/s, midgraft PSV 60
cm/s.
†19 grafts repaired for stenosis (mean PSV  368 cm/s), 11 graft throm-
bectomies.were 86%, 78%, and 62%, respectively (Fig 2). Intervention
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graft patency rates of 95% at 1 year and 88% at 5 years.
Eleven grafts had a secondary procedure for thrombosis.
Four grafts remained patent after thrombectomy or revi-
sion, and seven grafts ultimately failed, leading to aorto-
femoral bypass in three patients, femorofemoral bypass in
three, and no intervention in one. Despite a patent femo-
rofemoral bypass, progression of distal limb atherosclerotic
disease resulted in two patients undergoing above-knee
amputation of the receipt limb at 5 and 11 months, respec-
tively.
DISCUSSION
Although endovascular intervention has revolutionized
Fig 1. A, Iliac stent stenosis (left) and decreasedmidgra
and increase in midgraft PSV (right).the management of iliac artery occlusive disease, diffuseatherosclerotic disease often mandates bypass grafting as an
aortofemoral, axillofemoral, or a femorofemoral bypass, in
the case of advanced ipsilateral disease. The patency of
femorofemoral bypass is considered inferior to aortofemo-
ral or iliofemoral bypass, with 5-year primary and secondary
patency rates in the range of 55% and 75%, respectively.7-11
Excellent 5-year patency rates of 85% have recently been
reported when femorofemoral bypass is performed to repair
an AAA in conjunction with uniiliac stent-grafting or when
femoropopliteal vein is used as the conduit in the treatment
of prosthetic graft infection or symptomatic PAOD.5,6
These observations support the opinion that progres-
sion of inflow iliac artery disease is an important cause of
femorofemoral graft failure. Our review found that duplex
k systolic velocity (PSV, right).B,Normal iliac PSV (left)ft peaultrasound surveillance after femorofemoral bypass de-
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the reconstructions. The development of anastomotic ste-
nosis was less frequent, and the absence of demonstrable
changes in midgraft PSV during surveillance suggests out-
flow disease progression can be rejected as the primary
cause for femorofemoral graft failure.
For patients who adhered to the recommended surveil-
lance protocol, the interpretation of duplex testing as
showing no significant graft abnormality predicted patency
until the next examination date. No graft failure occurred
during the follow-up period with normal results (no steno-
sis identified and midgraft PSV 60 cm/s) on duplex
testing. Detection of a stenosis alone or combined with a
decrease in midgraft PSV to 60 cm/s correlated with
interval graft thrombosis or a clinical decision to proceed
with graft revision. All anastomotic and most iliac stent
stenoses identified by surveillance were repaired, but no
intervention or further diagnostic testing was recom-
mended to six patients with identified inflow iliac artery
stenosis. The decision to observe an inflow artery stenosis
contributed to more than half of the observed graft throm-
botic events.
The velocity spectra data recorded in this study support
the hypothesis that an acquired stenosis may reduce graft
flow (ie, midgraft PSV) and increases the risk for graft
thrombosis. A significantly greater number of grafts revised
for thrombosis or stenosis had a midgraft PSV 60 cm/s
compared with nonrevised, patent bypasses (P  .03); but
because of the range of measured values, the meanmidgraft
PSVs of revised and nonrevised grafts were not significantly
different. These observations are similar to a published
report on duplex surveillance of axillofemoral bypass grafts
that found thrombosis was more common when midgraft
velocity was 80 cm/s.13
Most reports on the failure of femorofemoral bypass
grafting deal with decision-making about the management
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Fig 2. Primary, assisted-primary, and secondary patency (Kaplan-
Meier life-table analysis) of 108 femorofemoral bypass grafts,
followed by duplex ultrasound surveillance.of the thrombosed bypass with essentially identical primaryand secondary patency rates calculated. In contrast, in this
study and in the report of D’Addio et al6 of femorofemoral
bypass with femoropopliteal vein, the assisted and second-
ary patency rates were significantly higher than the primary
patency rate at 3 and 5 years, both 90%. This can be
attributed to effective graft surveillance and successful re-
pair of duplex-detected stenosis. During the mean 3.5-year
follow-up period, one quarter of the patients had revision
of a failing patent bypass. Of the 19 secondary interven-
tions, 17 involved an endovascular procedure and only
three grafts that underwent revision failed during the
follow-up period.When a thrombosed femorofemoral graft
was encountered, salvage of the graft was attempted in less
than half (4 of 11) of the patients. Of note, only one graft
was lost to infection in this audit.
CONCLUSION
The outcome data of this retrospective review support a
recommendation of duplex surveillance after femorofemo-
ral bypass. The incidence of duplex-detected abnormalities
will be higher after prosthetic grafting for symptomatic
PAOD compared with prosthetic bypass in conjunction
with stent-graft AAA repair or when femoropopliteal vein is
the conduit. If an inflow iliac artery stenosis with a duplex-
measured PSV300 cm/s is detected, intervention should
be considered. We prefer proceeding directly to contrast
angiography for lesion verification and immediate endovas-
cular intervention if the anatomy is suitable for angioplasty.
In our experience, all iliac stent and native artery lesions
with PSVs above this threshold value were associated with a
60% angiographic stenosis and a significant (15 mm
Hg) resting systolic pressure gradient. No false-positive
duplex examinations occurred in this patient series.
A recent report from our group involving 28 patients
who underwent iliac stenting based on duplex testing alone
had a documented assisted primary patency of 100% at 2
years when duplex surveillance and reintervention for ste-
nosis was performed.14 Similar to infrainguinal bypass pro-
cedures, the duration of surveillance after femorofemoral
bypass should be life-long, as the mean time to interven-
tion for a duplex-detected stenosis in this study was approx-
imately 3 years. Other diagnostic modalities such as mag-
netic resonance angiography are not appropriate to
diagnose iliac stenting stenosis, and the application of com-
puted tomography angiography for arterial intervention
surveillance has yet to be proven. Duplex surveillance, as
outlined in this report with repair of lesions with PSVs
300 cm/s, should improve the long-term patency of
femorofemoral bypass grafts.
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Dr Joseph Mills (Tucson, Ariz). The present study has ex-
panded the application of surveillance to postoperative duplex
evaluation of primarily prosthetic femorofemoral bypass grafts.
Before asking questions of the authors, I would note that the
rationale underlying duplex surveillance of infrainguinal vein grafts
and that behind femorofemoral bypass grafts may be different, and
the two situations may not be comparable. The major premises
underlying duplex surveillance of infrainguinal vein grafts include
the following: (1) vein graft failure most often results from the
development of intrinsic graft stenosis, (2) high-grade vein graft
stenosis will lead to graft thrombosis if not revised, (3) vein graft
stenosis is often clinically silent and not reliably detectable before
graft occlusion by history, physical exam, and simple noninvasive
measurements, (4) vein graft stenoses and low flow states can be
accurately identified, graded, and monitored for progression by
duplex surveillance, (5) prophylactic revision of patent, but failing,
vein grafts yields superior results to those obtained after thrombec-
tomy or thrombolysis and revision of occluded vein grafts, and
(6) vein graft patency and limb salvage rates are significantly
improved by a postoperative duplex surveillance protocol.
Although most vascular surgeons accept these premises for
infrainguinal vein graft surveillance, these basic assumptions may
not apply at all to a prosthetic femorofemoral bypass graft. Femo-
rofemoral grafts can usually be readily resurrected either by revi-
sion and thrombectomy or by lysis and inflow angioplasty. In
addition, the consequences of femorofemoral bypass graft failure
do not appear to be as severe as for infrainguinal vein grafts. These
skeptical thoughts lead to the following questions:
Do you have data on howmany patients with duplex-detected
lesions postfemorofemoral bypass graft had either recurrent symp-
toms or reduced ankle-brachial index measurements and therefore
would have been discovered without duplex surveillance? How do
you assess the inflow prior to performing a femorofemoral bypass
graft?
In the manuscript, the authors note that five of the 11 femo-
rofemoral graft thromboses occurred in the first 6 months afteror progressive disease to have developed after inflow iliac angio-
plasty. Could some of these early graft events be related to inade-
quate inflow assessment or inadequate iliac angioplasty?
Did any patient with a femorofemoral bypass graft thrombosis
lose their leg? From reading the manuscript, it sounds as though
the two patients who required amputation had patent femoro-
femoral bypass grafts and presumably went on to amputation due
to uncorrectable or uncorrected outflow disease. Femorofemoral
graft thrombosis may not be nearly as morbid as infrainguinal vein
graft failure, and therefore, surveillancemay not be cost-effective in
the former circumstance.
Finally, we clearly need better velocity criteria and data on
progression of disease for iliac lesions, especially those proximal to
a femorofemoral bypass graft. The routine use of a peak systolic
velocity of 300 cm/s seems too simplistic and insufficiently spe-
cific. I would also note that midgraft peak systolic velocity is not
likely to be very helpful, since it may be greatly affected by whether
the graft is an 8-mm graft or a 6-mm graft. One should note there
are randomized, prospective trials demonstrating that 8-mm fem-
oropopliteal prosthetic grafts have greater long-term patency than
6-mm grafts, even though the midgraft velocities would be lower
due to the diameter of the conduit.
Dr. Stone.Okay, let me try to answer those questions. If you
looked at the patients we had who developed either a drop in ABI
of 0.2 or recurrent symptoms, that number is around a quarter, so
not all of our patients would have been picked up just based on
history and just basic physical exam in the office. Most of these
patients were asymptomatic at the time of detection of abnormal-
ities.
With regard to early thrombosis, again our patients had duplex
examinations prior to their femorofemoral bypass and it is curious
why we had early thrombosis in several of those patients. Again, if
you look at our results, most of the patients with early failures had
abnormal velocities and at least reviewing these charts myself, what
seemed to happen is you would have a patient come in and they
would have the left side occluded and the right side with a high
velocity. That side would be treated, and a femorofemoral bypass
